Genex Pharmaceutical Inc
Genex Pharmaceutical, Inc. produces and distributes Reconstituted Bone Xenograft (RBX) in the People's Republic of China. The RBX is a medical device that accelerates bone healing. The company distributes its medical devices to approximately 500 hospitals, as well as to other medical device customers. Genex Pharmaceutical, Inc. was founded in 2003 and is headquartered in Tianjin, the People's Rep… Read more
Genex Pharmaceutical Inc (GENX) - Net Assets
Latest net assets as of December 2007: $4.74 Million USD
Based on the latest financial reports, Genex Pharmaceutical Inc (GENX) has net assets worth $4.74 Million USD as of December 2007.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.65 Million) and total liabilities ($3.91 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.74 Million |
| % of Total Assets | 54.8% |
| Annual Growth Rate | 336.46% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 8609.99 |
Genex Pharmaceutical Inc - Net Assets Trend (2003–2007)
This chart illustrates how Genex Pharmaceutical Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Genex Pharmaceutical Inc (2003–2007)
The table below shows the annual net assets of Genex Pharmaceutical Inc from 2003 to 2007.
| Year | Net Assets | Change |
|---|---|---|
| 2007-12-31 | $4.74 Million | +16.55% |
| 2006-12-31 | $4.07 Million | +22.63% |
| 2005-12-31 | $3.32 Million | +26.91% |
| 2004-12-31 | $2.61 Million | +19905.94% |
| 2003-12-31 | $13.06K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Genex Pharmaceutical Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 261873400.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2007)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $2.53 Million | 53.33% |
| Common Stock | $1.78K | 0.04% |
| Other Comprehensive Income | $540.06K | 11.39% |
| Other Components | $1.67 Million | 35.24% |
| Total Equity | $4.74 Million | 100.00% |
Genex Pharmaceutical Inc Competitors by Market Cap
The table below lists competitors of Genex Pharmaceutical Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Protek Capital Inc.
PINK:PRPM
|
$0.97 |
|
Media Way Corp
PINK:MDAW
|
$0.97 |
|
Nexis International Industries Inc
PINK:NXSI
|
$0.97 |
|
SES Solar Inc
PINK:SESI
|
$0.97 |
|
Nextmart Inc
PINK:NXMR
|
$0.97 |
|
Kidville Inc
PINK:KVIL
|
$0.97 |
|
Terme Bancorp Inc
PINK:TMEB
|
$0.97 |
|
NeoMedia Technologies Inc
PINK:NEOM
|
$0.97 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genex Pharmaceutical Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2006 to 2007, total equity changed from 4,066,536 to 4,739,562, a change of 673,026 (16.6%).
- Net income of 342,549 contributed positively to equity growth.
- Other comprehensive income increased equity by 330,477.
Equity Change Factors (2006 to 2007)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $342.55K | +7.23% |
| Other Comprehensive Income | $330.48K | +6.97% |
| Total Change | $- | 16.55% |
Book Value vs Market Value Analysis
This analysis compares Genex Pharmaceutical Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | $0.00 | $0.00 | x |
| 2004-12-31 | $0.15 | $0.00 | x |
| 2005-12-31 | $0.19 | $0.00 | x |
| 2006-12-31 | $0.23 | $0.00 | x |
| 2007-12-31 | $0.27 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genex Pharmaceutical Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.23%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.58%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.82x
- Recent ROE (7.23%) is above the historical average (-64.00%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | -400.08% | -1500.29% | 0.16x | 1.69x | $-53.56K |
| 2004 | 38.78% | 43.12% | 0.80x | 1.12x | $751.96K |
| 2005 | 18.85% | 25.09% | 0.56x | 1.33x | $293.40K |
| 2006 | 15.22% | 25.39% | 0.42x | 1.41x | $212.31K |
| 2007 | 7.23% | 10.58% | 0.37x | 1.82x | $-131.41K |
Industry Comparison
This section compares Genex Pharmaceutical Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genex Pharmaceutical Inc (GENX) | $4.74 Million | -400.08% | 0.82x | $0.97 |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |